News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Endotis Pharma Reports The Successful Completion Of Phase I Clinical Trials Of The Neutralizable Anticoagulant EP217609 And Its Antidote Avidin Under Development For Use In Heart Surgery



4/30/2010 1:45:23 PM

Biocitech Park, Paris (France), April 30, 2010 - Endotis Pharma, the biopharmaceutical company dedicated to the discovery and development of small glyco-drugs, announced that the neutralizable anticoagulant EP217609 and its specific antidote avidin have successfully completed their respective first-in-man Phase I clinical trials.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES